Skip to Content

Clinical Trials Search Results

Showing 1-10 of 39

Sorted By:

  • Acorn MDV3100-11

    A Phase 2, Single-Arm, Open-Label, Multicenter Study of the Clinical Activity and Safetyof Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple-Negative Breast Cancer

  • Alliance A031201

    Phrase III trial of Enzalutamide versus Enzalutamide, Abiraterone, and Prednisone for Castration Resistant Metastatic Prostate Cancer

  • Amgen 20070622

    A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

  • Astex AT13397-05

    A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)

  • BMS CA209-118

    Lung Cancer Molecular Profiling & Clinical Outcomes in U.S. Community Oncology Practices

  • CALGB 50904

    A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib, and Bendamustine in Patients with Untreated Follicular Lymphoma

  • CALGB 80702

    A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

  • CTSU E1311

    A randomized, Placebo Controlled Phase II trial of Afatinib (BIBW2992) as Adjuvant Therapy following Chemoradiation in patients with Head and Neck squamous cell carcinoma at High risk of recurrence

  • CTSU E1A11

    Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

  • CTSU E5508

    A Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC.

Page of 4, showing trials 1-10 of 39

Also in this Section